# Patent Watch: Defloria Targets Autism With CW1AS1

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-defloria-targets-autism-with-cw1-2026-10-08/
> **Published:** 2026-10-08T15:03:50-04:00 | **Last Modified / Clinically Audited:** 2026-10-08T15:03:50-04:00
> **Clinical Summary:** The application identifies a cannabinoid extract designated CW1AS1 for treating autism and associated symptoms. The available disclosure does not specify a

---

PATENT WATCH
 PCTUS2026013391
 
 

# Patent Watch: Defloria Targets Autism With CW1AS1 Cannabinoid Extract

 
 **Assignee:** DEFLORIA LLC
 **Inventors:** JOEL STANLEY
 **Published:** 2026-01-30
 
 

 
 Invention Summary & Claims
 

The application identifies a cannabinoid extract designated CW1AS1 for treating autism and associated symptoms. The available disclosure does not specify active pharmaceutical ingredients, cannabinoid ratios, excipients, dosing, or delivery mechanisms, preventing a detailed assessment of the claimed composition or its novelty.

 

 

## Clinical Perspective & Therapeutic Significance

 

A reproducible cannabinoid formulation could warrant investigation for defined autism-associated symptoms, but this application does not establish improvements in core autism features or associated behavioral difficulties. Bioavailability and safety cannot be assessed without composition and dosing details, particularly for pediatric use, where sedation, [drug interactions](https://cedclinic.com/cbd-gummies-pain-management/), and potential THC exposure require careful evaluation.

 

## Intellectual Property & Market Landscape

 

Defloria LLC is identified as the applicant, with Joel Stanley listed as inventor, positioning the application around a named extract and an autism-focused therapeutic use. Unlike general-market cannabis products, the application frames the extract as a treatment, but the available disclosure does not establish pharmaceutical-grade standardization, regulatory authorization, or commercially defensible differentiation.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (PCTUS2026013391)](https://patents.google.com/patent/PCTUS2026013391/en).
 

 
 Editorial Commentary
 

The clinically meaningful opportunity is a standardized, rigorously tested treatment for clearly defined autism-associated symptoms, not a patent-based promise of benefit. This application merits monitoring, with its significance dependent on detailed claims, formulation characterization, and controlled clinical evidence.

 

 
 

### Frequently Asked Questions

 
 Does this patent mean the extract can treat autism?
 No. A patent application describes proposed intellectual property and therapeutic uses, not proof that a product safely or effectively treats autism or its associated symptoms.

 Has CW1AS1 been proven effective in clinical trials?
 The available patent disclosure does not identify clinical trial results demonstrating efficacy. Patent status is separate from clinical validation and regulatory approval.

 When could patients access this formulation?
 No therapeutic availability date can be established from this disclosure. Access to an authorized treatment would depend on product development, appropriate clinical evidence, and applicable regulatory requirements.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).